Formycon AG (FRA:FYB)
22.95
+0.30 (1.32%)
At close: Jan 30, 2026
Formycon AG Revenue
Formycon AG had revenue of 10.50M EUR in the quarter ending September 30, 2025, a decrease of -26.07%. This brings the company's revenue in the last twelve months to 48.07M, down -17.19% year-over-year. In the year 2024, Formycon AG had annual revenue of 69.67M, down -10.32%.
Revenue (ttm)
48.07M
Revenue Growth
-17.19%
P/S Ratio
8.45
Revenue / Employee
192.30K
Employees
245
Market Cap
406.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
| Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
| Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
| Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
| Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| FRoSTA Aktiengesellschaft | 652.00M |
| SIMONA Aktiengesellschaft | 586.42M |
| Südwestdeutsche Salzwerke AG | 347.96M |
| centrotherm international AG | 288.81M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Novabase S.G.P.S. | 130.35M |
| Wild Bunch AG | 68.86M |
| EUWAX Aktiengesellschaft | 41.42M |
Formycon AG News
- 19 days ago - EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, sell - Wallstreet:Online
- 19 days ago - EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, Verkauf • news - Onvista
- 5 weeks ago - EQS-News: FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco – Strengthening US Presence with Zydus as Commercialization Partner - Wallstreet:Online
- 7 weeks ago - Formycon AG: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada - Finanz Nachrichten
- 7 weeks ago - Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada - Wallstreet:Online
- 7 weeks ago - EQS-News: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada - Wallstreet:Online
- 2 months ago - Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda biosimilar candidate FYB206 for the MENA Region - Finanz Nachrichten
- 2 months ago - Formycon, MS Pharma Sign Commercialization Partnership For Keytruda Biosimilar - Nasdaq